Stockscreener 앱 받기
2.05
5.67%
0.11
시간 외 거래:
2.06
0.01
+0.49%
전일 마감가:
$1.94
열려 있는:
$1.93
하루 거래량:
4.69M
Relative Volume:
1.08
시가총액:
$860.87M
수익:
-
순이익/손실:
$-75.80M
주가수익비율:
-5.8571
EPS:
-0.35
순현금흐름:
$-68.07M
1주 성능:
+9.04%
1개월 성능:
-12.39%
6개월 성능:
-20.85%
1년 성능:
-31.21%
1일 변동 폭
$1.90
$2.07
1주일 범위
$1.81
$2.10
52주 변동 폭
$1.54
$3.97
Nuvation Bio Inc Stock (NUVB) Company Profile
명칭
Nuvation Bio Inc
전화
(415) 754-3517
주소
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
2.05 | 860.87M | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-03-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-26 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-05-04 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-06 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2021-03-08 | 개시 | BTIG Research | Buy |
| 2021-03-08 | 개시 | Cowen | Outperform |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Wedbush | Outperform |
모두보기
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus
Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus
RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times
Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria
Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com
Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com India
Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment - TipRanks
Nuvation Bio price target maintained at $6 by Citizens JMP - Investing.com South Africa
FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer - PharmExec
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
U.S. FDA Approves Nuvation Bio’s Ibtrozi - Contract Pharma
Nuvation Scores First FDA Nod With Oral Lung Cancer Drug - BioSpace
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtro - GuruFocus
FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer - PMLiVE
Nuvation Bio stock falls after FDA approves lung cancer drug By Investing.com - Investing.com Canada
FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC - The Pharma Letter
Nuvation Bio stock falls after FDA approves lung cancer drug - Investing.com
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi - MSN
Nuvation Bio (NUVB) Gains FDA Approval for Lung Cancer Drug Ibtr - GuruFocus
Nuvation Bio (NUVB) Trading Halted Amidst Anticipated Announceme - GuruFocus
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche - BioPharma Dive
Nuvation Bio’s IBTROZI Receives FDA Approval - TipRanks
Nuvation Set For First Launch With Ibtrozi In Lung Cancer - insights.citeline.com
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer Drug IBTROZI | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wed - GuruFocus
Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wedbush | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib By Investing.com - Investing.com South Africa
US FDA approves Nuvation Bio’s lung cancer therapy - WSAU
US FDA approves Nuvation Bio's rare lung cancer drug - Reuters
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZ - GuruFocus
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval - Benzinga
Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung - GuruFocus
Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtrozi | NUVB Stock News - GuruFocus
# FDA approves Nuvation Bio’s lung cancer drug taletrectinib - Investing.com
Nuvation Bio (NUVB) Trading Resumes | NUVB Stock News - GuruFocus
Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung Cancer | NUVB Stock News - GuruFocus
Nuvation Bio scores first FDA approval for new lung cancer drug - Endpoints News
Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer - GuruFocus
Nuvation kinase inhibitor wins FDA approval in non-small cell lung cancer - TipRanks
Nuvation Bio stock in focus as FDA clears Ibtrozi (NUVB:NYSE) - Seeking Alpha
Nuvation Bio announces FDA approval of Ibtrozi for advanced ROS-1+ NSCLC - TipRanks
FDA Grants Approval to Nuvation Bio's Ibtrozi for Lung Cancer Treatment (NUVB) | NUVB Stock News - GuruFocus
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Mid Florida Newspapers
Nuvation Bio (NUVB) Shares Surge Following FDA Approval | NUVB Stock News - GuruFocus
US FDA approves Nuvation Bio's lung cancer therapy - TradingView
Nuvation Bio Inc (NUVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvation Bio Inc 주식 (NUVB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sauvage Philippe | Chief Financial Officer |
Jun 17 '25 |
Buy |
1.79 |
4,000 |
7,160 |
9,902 |
| Sauvage Philippe | Chief Financial Officer |
Jun 16 '25 |
Buy |
1.83 |
3,300 |
6,056 |
5,902 |
| Sjogren Colleen | Chief Commercial Officer |
Jun 16 '25 |
Buy |
1.81 |
50,000 |
90,350 |
81,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 16 '25 |
Buy |
1.79 |
50,000 |
89,740 |
50,000 |
| Hung David | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
1.79 |
500,000 |
893,500 |
59,281,054 |
| Liu Dongfang | CHIEF MEDICAL OFFICER |
May 02 '25 |
Option Exercise |
1.94 |
20,000 |
38,800 |
32,000 |
| Liu Dongfang | CHIEF MEDICAL OFFICER |
May 02 '25 |
Sale |
2.50 |
20,000 |
50,024 |
12,000 |
1.45%
0.86%
자본화:
|
볼륨(24시간):